Genmab

Epcoritamab + lenalidomide + rituximab (R2) in relapsed or refractory follicular lymphoma (FL) shows 96% overall response rate (ORR), 87% complete response (CR), and 80% 21-month progression-free survival (PFS). Two-year overall survival (OS) rate is 90%. These results follow the FDA's breakthrough therapy designation (BTD) and support ongoing Phase 3 EPCORE FL-1 trial.

AbbVie announced updated results from the Phase 1b/2 EPCORE NHL-2 trial, showing 96% overall response rate (ORR) and 87% complete response (CR) rate in adult patients with relapsed or refractory follicular lymphoma (FL) treated with epcoritamab + lenalidomide + rituximab (R2). The data were presented at the 66th Annual Meeting of the American Society of Hematology (ASH).

Genmab's Phase 1b/2 EPCORE® NHL-2 trial showed 96% overall response rate and 87% complete response rate in relapsed/refractory follicular lymphoma patients, with 80% progression-free survival at 21 months and 90% two-year overall survival rate. FDA granted breakthrough therapy designation for the combination therapy. Adverse events included neutropenia (62%), cytokine release syndrome (51%), and COVID-19 complications affecting 57% of patients, leading to treatment discontinuation in 13% of cases, with five fatal outcomes.

The global Combination Antibody Therapy market is projected to grow from $178.1B in 2023 to $443B by 2030, driven by cancer prevalence, immunotherapy advancements, and personalized medicine. The report by ResearchAndMarkets.com offers insights into market trends, drivers, and forecasts.

Lundbeck initiates MASCOT, a phase III trial assessing amlenetug's efficacy and safety for Multiple System Atrophy (MSA). Amlenetug, a monoclonal antibody targeting extracellular α-synuclein, aims to slow MSA's clinical progression. The trial includes a 72-week double-blind phase and an open-label extension, conducted globally.

Jefferies lowers Genmab's price target, focusing on Q1 2025 when J&J may decide on Darzalex successor.

BioNJ launches 'Time Off for Clinical Trials' initiative, encouraging member companies to offer paid time off for employees to participate in clinical trials. Amicus Therapeutics, Bristol Myers Squibb, Genmab, PsychoGenics, PTC Therapeutics, and Sanofi are among the initial companies committed to implementing this policy.

BioNJ launches 'Time Off for Clinical Trials' initiative, encouraging member companies to offer paid time off for employees to participate in clinical trials. Amicus Therapeutics, Bristol Myers Squibb, Genmab, PsychoGenics, PTC Therapeutics, and Sanofi are among the first to commit. The initiative aims to remove barriers to participation in clinical trials, particularly for hourly workers and underrepresented populations.

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO and DARZALEX SC for high-risk smoldering multiple myeloma, supported by Phase 3 AQUILA study data, aiming to shift treatment paradigm.